FDA approves IND application for peanut allergen vaccine. Phase I study in peanut allergy patients to begin May 2022

Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022 Topline data from first-in-human trial expected in H1 2023 Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of …

Read More

Peanut allergy vaccine takes big step forward with first human tests

From The Telegraph, By Julia Bradshaw If clinical trials are successful, the British-developed jab could be available to patients within four to five years The world is one step closer to a vaccine against peanut allergy after UK biotech Allergy Therapeutics announced plans to test its jab in human clinical trials. The company, which was …

Read More

Saiba AG focuses on a future COVID-19 vaccine with advantages over first to market vaccine candidates

Saiba AG has decided to focus on optimization of its vaccine candidate rather than rush into clinical studies in 2020.

Read More

Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH

Group to investigate potential of VLP technology in oncology and other immune conditions after encouraging proof of concept findings Builds on positive ongoing progress in VLP-based peanut allergy candidate vaccine VLP platform to be combined with Allergy Therapeutics’ proprietary adjuvant technology Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy …

Read More

Saiba AG Selects AGC Biologics to Develop and Produce COVID-19 Vaccine

Saiba proprietary technology has enabled scientists to generate a vaccine candidate against COVID-19 with preclinical proof-of-concept.

Read More

Saiba AG Shows encouraging preclinical data for its COVID-19 VLP-based vaccine

(PFÄFFIKON), March 25, 2020 — Saiba AG, https://www.saiba-biotech.com/ , has developed a proprietary platform technology based on immunologically optimized virus-like particles. This platform technology has now enabled scientists to establish preclinical proof-of-concept for a vaccine against COVID-19. The vaccine candidate has been able to induce in test animals high levels of antibodies that neutralize the …

Read More

  • Recent Publications

    Saiba scientists published in collaboration with different universities a number of ground-braking publications underscoring the power of the Saiba vaccination platform.

    Lisha Zha, Xinyue Chang, Hongxin Zhao, Mona O. Mohsen, Liang Hong, Yuhang Zhou, Hongquan Chen , Xuelan Liu, Jie Zhang, Dong Li, Ke Wu, Byron Martina, Junfeng Wang, Monique Vogel and Martin F. Bachmann. Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles. MDPI Vaccines. 2021 April. doi: 10.3390/vaccines9040395.

    Download the article

    Martin F. Bachmann, Mona O. Mohsen, Lisha Zha, Monique Vogel and Daniel E. Speiser. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. 2021 January. Nature npj Vaccines. doi: 10.1038/s41541-020-00264-6

    Download the article

    Fettelschoss-Gabriel A, Fettelschoss V, Olomski F, Birkmann K, Thoms F, Bühler M, Kummer M, Zeltins A, Kündig TM, Bachmann MF. Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses.
    Allergy. 2018 Nov 7. doi: 10.1111/all.13659.

    Cabral-Miranda G, Cardoso AR, Ferreira LCS, Sales MGF, Bachmann MF (2018) Biosensor-based selective detection of Zika virus specific antibodies in infected individuals. Biosens Bioelectron. 2018 Aug 15;113:101-107. doi: 10.1016/j.bios.2018.04.058. Epub 2018 May

    Martin F. Bachmann, Andris Zeltins, Gints Kalnins, Ina Balke, Nina Fischer, Ana Rostaher Kaspars Tars, Claude Favrot (2018). Vaccination against IL-31 for the treatment of atopic dermatitis in dogs., JACI, in press

    Antonia Fettelschoss-Gabriel, Victoria Fettelschoss, Thomas M. Kündig, Martin F. Bachmann. (2018) Treating insect bite hypersensitivity (IBH) in horses by active vaccination against Interleukin-5 JACI, in press

    Gustavo Cabral-Miranda, Matthew D. Heath, Aadil El-Turabi, Ahmed M. Salman, Ariane C. Gomes, Eduardo Montoya-Diaz, Erwan Atcheson, Murray A Skinner, Matthias F. Kramer, Arturo Reyes-Sandoval, Martin F Bachmann (2017) Microcrystalline tyrosine (MCT): a depot adjuvant licensed in allergy offers new opportunities in malaria, Vaccines, in press. Impact: 1.8

    Andris Zeltins, Jonathan West, Franziska Zabel, Aadil El-Turabi, Ina Balke, Stefanie Haas, Melanie Maudrich, Federico Storni, Paul Engeroff, Gary T Jennings, Abhay Kotecha, David I Stuart, John Foerster, Martin F Bachmann (2017) Incorporation of Tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy. Nature PJ Vaccines, in press

    P. Engeroff, M. Fellmann, D. Yerly, M.F. Bachmann and M. Vogel (2017) IgE-dependent antigen recycling in human B cells facilitates transfer to dendritic cells and antigen presentation. JACI, in press. Impact: 12.5

    Lisha Zha, Fabiana Leoratti, Federico Storni, Dr.Monique Vogel and
    Martin Fabian Bachmann (2017). An unexpected protective role of low affinity allergen-specific IgG via the inhibitory receptor FcgRIIb. JACI, in press. Impact: 12.5

    Cabral-Miranda G, Heath MD, Mohsen MO, Gomes AC, Engeroff P, Flaxman A, Leoratti FMS, El-Turabi A, Reyes-Sandoval A, Skinner MA, Kramer MF, Bachmann MF.Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax. Vaccines (Basel). 2017 May 2;5(2). Impact: 1.8

    Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines. Leneghan DB, Miura K, Taylor IJ, Li Y, Jin J, Brune KD, Bachmann MF, Howarth M, Long CA, Biswas S. Sci Rep. 2017 Jun 19;7(1):3811. Impact: 4.8

    Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells. Engeroff P, Caviezel F, Storni F, Thoms F, Vogel M, Bachmann MF.
    Allergy. 2017 Aug 8. doi: 10.1111/all.13268. Impact: 6.5

    Doucet M, El-Turabi A, Zabel F, Hunn BHM, Bengoa-Vergniory N, Cioroch M, Ramm M, Smith AM, Gomes AC, Cabral de Miranda G, Wade-Martins R, Bachmann MF Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS One. 2017 Aug 10;12(8):e0181844. Impact: 4

    Gomes AC, Flace A, Saudan P, Zabel F, Cabral-Miranda G, Turabi AE, Manolova V, Bachmann MF. Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines. Front Immunol. 2017 Mar 6;8:226. doi: 10.3389/fimmu.2017.00226. eCollection 2017 Mar 6. Impact:6.5

    Mohsen MO, Gomes AC, Cabral-Miranda G, Krueger CC, Leoratti FM, Stein JV, Bachmann MF. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. J Control Release. 2017 Apr 10;251:92-100. doi: 10.1016/j.jconrel.2017.02.031. Epub 2017 Feb 28. Impact: 6

    Ana R. Cardoso, Gustavo Cabral-Miranda, Arturo Reyes-Sandoval, Martin F Bachmann and M. Goreti F. Sales. Detecting circulating antibodies by controlled surface modification with specific target proteins: Application to malaria. Biosensors and Bioelectronics. May 15;91:833-841. doi: 10.1016/j.bios.2017.01.031. Epub 2017 Jan 15. Impact: 7.8

    Eduardo Alves, Ahmed M. Salman, Fabiana Leoratti, Cesar Lopez-Camacho, Martha Eva Viveros-Sandoval, Amar Lall, Aadil El-Turabi, Martin F. Bachmann, Adrian V.S. Hill, Chris J. Janse, Shahid M. Khan and Arturo Reyes-Sandoval. Evaluation of PvCelTOS as a pre-erythrocytic P. vivax vaccine. Clinical and Vaccine Immunology, 2017 Apr 5;24(4). pii: e00501-16. , impact: 2.5

    Zabel F, Fettelschoss A, Vogel M, Johansen P, Kündig TM, Bachmann MF. Distinct T helper cell dependence of memory B-cell proliferation versus plasma cell differentiation.. Immunology. 2016 Nov 9. doi: 10.1111/imm.12688 Impact: 3.6

    Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, Biswas S, Howarth M. Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization. Sci Rep. 2016 Jan 19;6:19234.

    Cavelti-Weder C, Timper K, Seelig E, Keller C, Osranek M, Lässing U, Spohn G, Maurer P, Müller P, Jennings GT, Willers J, Saudan P, Donath MY, Bachmann MF.
    Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes.
    Mol Ther. 2016 May;24(5):1003-12.

    Zabel F, Mohanan D, Bessa J, Link A, Fettelschoss A, Saudan P, Kündig TM, Bachmann MF. Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies.
    J Immunol. 2014 Jun 15;192(12):5499-508.

    Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, Schwarz K, Johansen P, Jennings GT, Bachmann MF. Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes. Mol Ther Methods Clin Dev. 2014 Oct 22;1:14048. doi: 10.1038/mtm.2014.48. eCollection 2014.

  • Reviews and Commentaries

    Bachmann MF, Whitehead P. (2013) Active immunotherapy for chronic diseases.
    Vaccine. 31:1777-84
    Impact: 3.5

    Reyes-Sandoval A, Bachmann MF. (2013) Plasmodium vivax malaria vaccines: Why are we where we are? Hum Vaccin Immunother. 9:.
    Impact: 3.1

    Zabel F., Kündig, TM and Bachmann MF. (2013) Virus-induced humoral immunity: on how B cell responses are initiated. Curr Opin Virol. 2013 3:357-62.
    Impact: 2.5

    Bachmann MF, Whitehead P. (2013) Active immunotherapy for chronic diseases.
    Vaccine. 31:1777-84.
    Impact: 3.5

    Fettelschoss A, Zabel F, Bachmann MF. Vaccination against Alzheimer disease: an update on future strategies. Hum Vaccin Immunother. 2014;10(4):847-51.

    Klimek L, Bachmann MF, Senti G, Kündig TM. Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. Expert Rev Clin Immunol. 2014 Aug;10(8):1059-67.

    Kündig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF.
    Is The Allergen Really Needed in Allergy Immunotherapy? Curr Treat Options Allergy. 2015;2(1):72-82.

    Förster J and Bachmann MF. Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments Nanomedicine (Lond.) (2015) 10(8), 1361–1369
    Bachmann MF, Kündig TM. Allergen specific immunotherapy: is it vaccination against toxins after all? Allergy. 2016 Aug 24.

    Gomes AC, Mohsen M, Bachmann MF. Harnessing Nanoparticles for Immunomodulation and Vaccines. Vaccines (Basel). 2017 Feb 14;5(1). pii: E6. doi: 10.3390/vaccines5010006. Impact: 1.8

    Pumpens P, Renhofa R, Dishlers A, Kozlovska T, Ose V, Pushko P, Tars K, Grens E, Bachmann MF. The True Story and Advantages of RNA Phage Capsids as Nanotools. Intervirology. 2016;59(2):74-110. Impact: 1.8

    Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017 Sep 5. Impact: 9.6

    Bachmann MF, Jennings GT, Vogel M. A vaccine against Alzheimer`s disease: anything left but faith? Expert Opin Biol Ther. 2019 Jan;19(1):73-78. doi: 10.1080/14712598.2019.1554646. Epub 2018 Dec 1

    Engeroff P, Bachmann MF. The 5th Virus-like Particle and Nano-Particle Vaccines (VLPNPV) conference. Expert Rev Vaccines. 2018 Dec 10. doi: 10.1080/14760584.2019.1557522.

    Bachmann MF, El-Turabi A, Fettelschoss-Gabriel A, Vogel M. The Prospects of an Active Vaccine Against Asthma Targeting IL-5. Front Microbiol. 2018 Oct 24;9:2522. doi: 10.3389/fmicb.2018.02522.
    5.

    Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. Mohsen MO, Gomes AC, Vogel M, Bachmann MF.
    Vaccines (Basel). 2018 Jul 2;6(3). pii: E37. doi: 10.3390/vaccines6030037